TEM Tempus AI, Inc.
TEM Tempus AI, Inc.
Healthcare · Health Information Services
Market read
Scan convergence 1 scan as of 2026-08-14 1 neutral converging
POC $50.04 · VWAP $65.00 · -20.6% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
3 watchlists
TEM Price Structure
Loading timeframes…
Peers
Every watchlist TEM belongs to, members best 30-day change first — TEM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@ibb
@ai-scan
Reported the quarter ending 2026-03-31: revenue $348M, diluted EPS $-0.71, net income $-126M (SEC filing, corroborated by the desk's provider cache). Across the print the stock moved -4.1% (close before → first close after).
full note →Against street estimates
How TEM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about TEM from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 24 days ago · Jul 25
- Tempus AI To Acquire Personalis for $1.5 Billion
- Tempus AI Announces Definitive Agreement to Acquire Personalis in Strategic All-Stock Merger Enhancing AI-Driven Oncology and Genomic Testing Capabilities
- Tempus AI to acquire Personalis in $1.5B MRD deal | TEM 8-K ...
- Tempus AI Announces Merger Agreement to Acquire Personalis
- Tempus AI to acquire Personalis in $1.7B deal | TEM SEC Filing - Form 425
TEM research tape
30 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.